FDA permits marketing of software to alert providers of potential strokes in patients
Editor's Note
The Food & Drug Administration (FDA) on February 13 announced that it is permitting the marketing of clinical decision support software that alerts providers to potential strokes in their patients.
The Viz.AI Contact application is designed to analyze computed tomography images of the brain and send a text notification to a neurovascular specialist if a suspected large vessel blockage is identified.
The algorithm will automatically notify the specialist during the same time the first-line provider is conducting a standard review of the images, involving the specialist sooner than the usual standard of care.
Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients. A stroke is a serious medical condition that requires emergency care and can cause lasting brain damage, long-term disability or even death.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO